X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (391) 391
primary myelofibrosis - physiopathology (259) 259
male (188) 188
female (159) 159
middle aged (150) 150
aged (130) 130
adult (116) 116
hematology (106) 106
index medicus (100) 100
primary myelofibrosis - pathology (96) 96
primary myelofibrosis - complications (94) 94
myelofibrosis (81) 81
primary myelofibrosis - diagnosis (54) 54
oncology (53) 53
bone marrow - pathology (52) 52
idiopathic myelofibrosis (50) 50
hematopoiesis, extramedullary (47) 47
polycythemia-vera (47) 47
primary myelofibrosis - etiology (45) 45
myeloid metaplasia (44) 44
primary myelofibrosis - therapy (44) 44
animals (43) 43
hematopoiesis (41) 41
primary myelofibrosis - genetics (40) 40
splenectomy (40) 40
essential thrombocythemia (39) 39
agnogenic myeloid metaplasia (38) 38
primary myelofibrosis - blood (37) 37
prognosis (37) 37
polycythemia vera - physiopathology (34) 34
mutation (33) 33
myeloproliferative disorders (32) 32
primary myelofibrosis - drug therapy (32) 32
spleen - physiopathology (32) 32
primary myelofibrosis (31) 31
aged, 80 and over (30) 30
diagnosis, differential (30) 30
myeloproliferative disorders - physiopathology (30) 30
biopsy (28) 28
janus kinase 2 - genetics (28) 28
medicine, general & internal (25) 25
pathology (25) 25
primary myelofibrosis - diagnostic imaging (25) 25
erythropoiesis (23) 23
extramedullary hematopoiesis (23) 23
mice (23) 23
myeloproliferative neoplasms (23) 23
leukemia (21) 21
splenomegaly - etiology (21) 21
fibrosis (20) 20
radionuclide imaging (19) 19
splenomegaly - physiopathology (19) 19
diagnosis (18) 18
polycythemia vera - complications (18) 18
retrospective studies (18) 18
bone marrow (17) 17
disease progression (17) 17
liver - physiopathology (17) 17
primary myelofibrosis - metabolism (17) 17
risk factors (17) 17
tomography, x-ray computed (17) 17
tyrosine kinase jak2 (17) 17
bone marrow - physiopathology (16) 16
chronic myeloproliferative disorders (16) 16
myeloproliferative disorders - genetics (16) 16
pathogenesis (16) 16
polycythemia vera (16) 16
polycythemia vera - genetics (16) 16
thrombocythemia, essential - physiopathology (16) 16
anemia (15) 15
medicine & public health (15) 15
adolescent (14) 14
child (14) 14
fatal outcome (14) 14
spleen - pathology (14) 14
bone-marrow (13) 13
cell biology (13) 13
follow-up studies (13) 13
health aspects (13) 13
jak2 (13) 13
liver - pathology (13) 13
megakaryocytes (13) 13
megakaryocytes - pathology (13) 13
primary myelofibrosis - surgery (13) 13
ruxolitinib (13) 13
stem cells (13) 13
time factors (13) 13
treatment outcome (13) 13
disease models, animal (12) 12
genetic aspects (12) 12
janus kinase 2 - antagonists & inhibitors (12) 12
thrombocythemia, essential - genetics (12) 12
chromium isotopes (11) 11
chronic disease (11) 11
chronic myelogenous leukemia (11) 11
classification (11) 11
disorders (11) 11
expression (11) 11
myeloproliferative disorders - pathology (11) 11
pediatrics (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (331) 331
German (20) 20
French (12) 12
Japanese (12) 12
Russian (9) 9
Spanish (8) 8
Italian (6) 6
Polish (2) 2
Chinese (1) 1
Czech (1) 1
Hebrew (1) 1
Hungarian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Journal of Oncology Nursing, ISSN 1092-1095, 2014, Volume 18, Issue 3, pp. 330 - 337
Journal Article
American Journal of Pathology, The, ISSN 0002-9440, 2012, Volume 181, Issue 3, pp. 858 - 865
Philadelphia chromosome–negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocytosis, and myelofibrosis, are disorders... 
Pathology | MURINE MODEL | RESVERATROL | POLYCYTHEMIA-VERA | MUTATION | TYROSINE KINASE JAK2 | MYELOPROLIFERATIVE NEOPLASMS | DISORDERS | PATHOLOGY | ESSENTIAL THROMBOCYTHEMIA | MYELOID METAPLASIA | RUXOLITINIB | Small Molecule Libraries - pharmacology | Spleen - physiopathology | Splenomegaly - drug therapy | Stilbenes - therapeutic use | Humans | Hyperplasia | Reticulin - drug effects | Spleen - drug effects | Splenomegaly - pathology | Stilbenes - pharmacology | Primary Myelofibrosis - blood | STAT5 Transcription Factor - metabolism | Splenomegaly - complications | Mice, Mutant Strains | Janus Kinase 2 - metabolism | Myeloid Cells - drug effects | Phosphorylation - drug effects | Spleen - pathology | Hematopoiesis, Extramedullary - drug effects | Janus Kinase 2 - antagonists & inhibitors | Bone Marrow - drug effects | Disease Models, Animal | Primary Myelofibrosis - drug therapy | Mice, Inbred C57BL | Primary Myelofibrosis - physiopathology | Small Molecule Libraries - therapeutic use | Reticulin - metabolism | Splenomegaly - physiopathology | Primary Myelofibrosis - enzymology | Megakaryocytes - pathology | Animals | Protein Kinase Inhibitors - therapeutic use | Bone Marrow - pathology | Amino Acid Substitution - genetics | Mice | Protein Kinase Inhibitors - pharmacology | Myeloid Cells - pathology | Megakaryocytes - drug effects | Regular
Journal Article
Journal Article
Journal Article
Mediators of Inflammation, ISSN 0962-9351, 2015, Volume 2015, pp. 145293 - 16
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 11/2015, Volume 19, Issue 11, pp. 2564 - 2574
JAK2 inhibition therapy is used to treat patients suffering from myeloproliferative neoplasms (MPN). Conflicting data on this therapy are reported possibly... 
myeloproliferative neoplasms | preclinical murine models | fibrosis | JAK2 inhibitor | Preclinical murine models | Fibrosis | Myeloproliferative neoplasms | MYELOFIBROSIS | MEDICINE, RESEARCH & EXPERIMENTAL | JAK2(V617F) | POLYCYTHEMIA-VERA | MECHANISM | EFFICACY | RUXOLITINIB | CELL BIOLOGY | HEMATOPOIETIC-CELLS | MURINE MODEL | MUTATIONS | EXPRESSION | Thrombocythemia, Essential - drug therapy | Primary Myelofibrosis - drug therapy | Thrombocythemia, Essential - physiopathology | Splenomegaly - drug therapy | Primary Myelofibrosis - physiopathology | Polycythemia Vera - blood | Pyrrolidines - administration & dosage | Thrombocythemia, Essential - blood | Disease Progression | Primary Myelofibrosis - blood | Protein Kinase Inhibitors - administration & dosage | Animals | Platelet Count | Polycythemia Vera - drug therapy | Mice | Janus Kinase 2 - antagonists & inhibitors | Polycythemia Vera - physiopathology | Sulfonamides - administration & dosage | Transforming growth factors | Health aspects | Stem cells | Tumors | Spleen | Bone marrow | Rodents | Erythropoiesis | Splenomegaly | Therapy | Polycythemia vera | Kinases | Neoplasms | Blockage | Biomedical materials | Blood platelets | Polycythemia | Janus kinase 2 | Osteosclerosis | Inhibition | Phenotypes | Dysplasia | Myelofibrosis | Cytokines | Anemia | Progenitor cells | Mutation | Platelets | Original
Journal Article
Lupus, ISSN 0961-2033, 3/2010, Volume 19, Issue 3, pp. 313 - 316
Journal Article
Journal Article
Journal Article